IRVINE, Calif., April 4, 2008 /PRNewswire-FirstCall/ -- IDM Pharma,
 Inc. (Nasdaq:   IDMI) announced today the appointment of Gregory J. Tibbitts
 to its board of directors, effective April 3, 2008. Mr. Tibbitts is
 currently the chief financial officer for CryoCor, Inc. (Nasdaq:   CRYO), a
 San Diego-based medical device company and in this role has overseen the
 transition from a private to public company, as well as from a clinical
 stage company to the current commercial operation.
 
     "Greg's extensive financial experience will be an asset to IDM Pharma's
 board of directors," said Timothy P. Walbert, president and chief executive
 officer of IDM Pharma. "In senior positions at both privately-held and
 publicly-traded companies, Greg has proven himself to be an executive with
 strong integrity and outstanding leadership abilities."
 
     During his more than 19 years in the financial and pharmaceutical
 industries, Mr.Tibbitts has held senior positions in a number of other
 companies including chief financial officer at Elitra Pharmaceuticals, a
 privately held drug discovery company. In addition, Mr. Tibbitts served as
 senior manager at Ernst & Young LLP and division controller at ITT
 Residential Capital.
 
     Mr. Tibbitts received a bachelor's degree from the University of San
 Diego and a master's degree from San Diego State University, and is a
 Certified Public Accountant.
 
     About IDM Pharma
 
     IDM Pharma is focused on the development of innovative cancer products
 that either destroy cancer cells by activating the immune system or prevent
 tumor recurrence by triggering a specific adaptive immune response. IDM
 Pharma is dedicated to maximizing the full therapeutic and commercial
 potential of each of its innovative products to address the needs of
 patients and the physicians who treat these patients.
 
     For more information about the company and its products, visit
 http://www.idm-pharma.com.
 
     Forward-Looking Statements
 
     This press release includes forward-looking statements that reflect
 management's current views of future events including statements regarding
 the Company's business activities and Mr. Tibbitts' participation on the
 Company's Board of Directors. Actual results may differ materially from the
 forward-looking statements due to a number of important factors, including,
 but not limited to, whether the Company will be able to provide assurance
 regarding the quality of the existing L-MTP-PE data and to respond to the
 remaining issues with regard to the MAA, including verification of data
 quality and CMC items, to the satisfaction of the CHMP, whether the final
 opinion of the CHMP will be consistent with the non-binding opinion of the
 CHMP, whether the European Commission will follow the final opinion of the
 CHMP once issued, whether the timing for the final opinion of the CHMP and
 the regulatory decision in Europe will occur as expected by the Company,
 the possibility that additional data from the Phase 3 clinical trial of
 L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE
 submitted by the Company may not provide adequate support for regulatory
 approval of L-MTP-PE in the United States within the timeframe expected by
 the Company, if at all, whether the Company will be able to manufacture and
 commercialize L-MTP-PE even if it is approved by regulatory authorities,
 and whether the cash resources of the Company will be sufficient to fund
 operations as planned. These and other risks affecting the Company and its
 drug development programs, intellectual property rights, personnel and
 business are more fully discussed in the Company's Annual Report on Form
 10-K filed with the SEC for the year ended December 31, 2007 and other
 periodic reports filed with the SEC. The Company expressly disclaims any
 intent or obligation to update these forward-looking statements, except as
 required by law.
 
 
 

SOURCE IDM Pharma Inc.

Back to top